Veracyte | VCYT - Operating Profit


Veracyte reported $19.08M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Agilent USD 399M 46M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Bruker USD 10.2M 66.1M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Illumina USD 239M 17M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Laboratory Of America USD 410.1M 28.1M Mar/2026
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Siemens EUR 2.57B 3M Dec/2025
Sonic Healthcare AUD 435.76M 193.66M Dec/2024
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Veracyte USD 19.08M 5.55M Mar/2026
Waters USD 148M 122.52M Mar/2026